Findings from the phase III TALAPRO-2 trial were presented by Agarwal et al at the 2023 ASCO Genitourinary Cancers Symposium (Abstract LBA17). The primary analysis investigated the efficacy of talazoparib plus enzalutamide vs placebo plus enzalutamide, in terms of imaging-based progression-free survival, in patients with metastatic castration-resistant prostate cancer.
